Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

Barlow, Ashley; Landolf, Kaitlin; Barlow, Brooke; Yeung, Siu Yan Amy; Heavner, Jason; Claassen, Cassidy W.; Heavner, Mojdeh

doi:10.1002/phar.2398

Cited by 205 publications

(266 citation statements)

References 94 publications

(126 reference statements)

Supporting

Mentioning

252

Contrasting

Unclassified

Order By: Relevance

“…[ 33 , 34 ] Therefore, there is still no widely accepted standard on specific drugs or the best drug treatment options of COVID-19. [ 35 – 37 ]…”

Section: Resultsmentioning

confidence: 99%

The COVID-19 research landscape

Wang

Hong

2020

Medicine

View full text Add to dashboard Cite

Objectives: The Coronavirus Disease 2019 (COVID-19) caused heavy burdens and brought tremendous challenges to global public health. This study aimed to investigate collaboration relationships, research topics, and research trends on COVID-19 using scientific literature. Method: COVID-19-related articles published from January 1 to July 1, 2020 were retrieved from PubMed database. A total of 27,370 articles were included. Excel 2010, Medical Text Indexer (MTI), VOSviewer, and D3.js were used to summarize bibliometric features. Results: The number of the COVID-19 research publications has been continuously increasing after its break. United States was the most productive and active country for COVID-19 research, with the largest number of publications and collaboration relationships. Huazhong University of Science and Technology from China was the most productive institute on the number of publications, and University of Toronto from Canada ranked as Top 1 institute for global research collaboration. Four key research topics were identified, of which the topic of epidemiology and public health interventions has gathered highest attentions. Topic of virus infection and immunity has been more focused during the early stage of COVID-19 outbreak compared with later stage. The topic popularity of clinical symptoms and diagnosis has been steady. Conclusions: Our topic analysis results revealed that the study of drug treatment was insufficient. To achieve critical breakthroughs of this research area, more interdisciplinary, multi-institutional, and global research collaborations are needed.

show abstract

“…[ 33 , 34 ] Therefore, there is still no widely accepted standard on specific drugs or the best drug treatment options of COVID-19. [ 35 – 37 ]…”

Section: Resultsmentioning

confidence: 99%

The COVID-19 research landscape

Wang

Hong

2020

Medicine

View full text Add to dashboard Cite

show abstract

“…The safety profile for RDV is acceptable with GI symptoms and has the most common side effects, including nausea, vomiting and rectal bleeding. Some patients also experience elevations in liver enzymes [86]. A very recent case study was published showing the advantage of delayed administration of RDV to patients with severe SAR-COV-2-associated pneumonia.…”

Section: Antiviral Agentsmentioning

confidence: 99%

COVID-19 Pandemic: an Overview of epidemiology, pathogenesis, Diagnostics and Potential Vaccines and Therapeutics

et al. 2020

View full text Add to dashboard Cite

At the time of writing this review, severe acute respiratory coronavirus syndrome-2 (SARS-CoV-2) has infected more than 2,355,853 patients and resulted in more than 164,656 deaths worldwide (as of 20 April 2020). This review highlights the preventive measures, available clinical therapies and the potential of vaccine development against SARS-CoV-2 by taking into consideration the strong genetic similarities of the 2003 epidemic SARS-CoV. Recent studies are investigating the repurposing of US FDA-approved drugs as there is no available vaccine yet with many attempts under clinical evaluation. Several antivirals, antimalarials and immunomodulators that have shown activity against SARS-CoV and Middle East coronavirus respiratory syndromes are being evaluated. In particular, hydroxychloroquine, remdesivir, favipiravir, arbidol, tocilizumab and bevacizumab have shown promising results. The main aim of this review is to provide an overview of this pandemic and where we currently stand. Graphical abstract:

show abstract

“…They reported that QTc prolonged maximally from baseline between days 3 and 4, in 30% of patients QTc increased by greater than 40 ms and in 11% of patients QTc increased to >500 ms, representing high-risk group for arrhythmia. The development of acute renal failure but not baseline QTc was a strong predictor of extreme QTc prolongation 11 .…”

Section: Hydroxychloroquine and Chloroquinementioning

confidence: 90%

Antiviral treatment of COVID-19

2020

View full text Add to dashboard Cite

IntroductionCurrently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate course, up to 5-10% can have severe , potentially life threatening course, there is an urgent need for effective drugs [1]. Optimized supportive care remains the mainstay of therapy. As new data regarding clinical characteristics, treatment options, and outcomes for COVID-19 emerges approximately every hour, physicians who are in the care of patients should keep themselves up to date on this issue. There have been more than 300 clinical trials going on, and some of them will be published in the next couple of months. The WHO is launching "Solidarity" clinical trial for COVID-19 treatments to further evaluate remdesivir, hydroxychloroquine/chloroquine, and lopinavir-ritonavir with and without interferon beta 1 . Various other antiviral and immunomodulating agents are 1 World Health Organization (2020). "Solidarity" clinical trial for COVID-19 treatments [online]. Website https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19treatments [accessed 12 April 2020]. 2 Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden5 L et al. Infectious DiseasesSociety of America Guidelines on the Treatment and Management of Patients with COVID-19 Infection [online]. Website https://www.idsociety.org/globalassets/idsa/ practice-guidelines/covid-19/treatment/idsa-covid-19-gl-tx-and-mgmt-4-11-20-1058-am-edt.pdf [accessed 12 April 2020].in various stages of evaluation for COVID-19. A registry of international clinical trials can be found on the WHO website and at ClinicalTrials.gov.At the moment, it is strongly recommended that patients be recruited into ongoing trials, which would provide much-needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not determine whether the benefits outweigh harms for most treatments [2] 2 .Unless used in the context of randomized clinical trials, antivirals will not be proved to be efficacious or safe for the treatment of COVID-19. In the 2014 Ebola outbreak, close to 30, 000 individuals developed Ebola viral disease, and numerous therapies were tested against this virus, including chloroquine, hydroxychloroquine, favipiravir, brincidofovir, monoclonal antibodies, antisense RNA, and convalescent plasma, among many others. With such a large number of therapeutic interventions given to affected Abstract: Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe, potentially life threatening course, there is an urgent need for effective drugs. Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviral and immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be publish...

show abstract

Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019

Cited by 205 publications

References 94 publications

The COVID-19 research landscape

The COVID-19 research landscape

COVID-19 Pandemic: an Overview of epidemiology, pathogenesis, Diagnostics and Potential Vaccines and Therapeutics

Antiviral treatment of COVID-19

Contact Info

Product

Resources

About